Trimodal (18)F-choline-PET/mpMRI/TRUS Targeted Prostate Biopsies in Prostate Cancer Patients
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Prostatic Neoplasm
- Sponsor
- Lille Catholic University
- Enrollment
- 31
- Primary Endpoint
- Number of image guided prostate biopsy in the zones detected by the TEP scan
- Status
- Completed
- Last Updated
- 9 years ago
Overview
Brief Summary
Prostate cancer is the first cancer in humans (25%). The most widely used tracer in oncology, the 18-Fluoro DeoxyGlucose does not allow the study of prostatic neoplasia. On the other hand, Choline, which is an amino alcohol, is involved in the synthesis of cell membranes and has an affinity for prostate cells. Its concentration is directly proportional to cell proliferation. The analogue of choline has the advantage of having a rapid and stable accumulation over time in cancer cells, with a rapid urinary excretion (4 minutes after injection).
The goal of this study is to assess the feasibility and the accuracy for targeting image guided prostate biopsy to detect prostate cancer after Imaging fusion of choline-PET/CT compared to 1.5T multiparametric magnetic resonance imaging (mpMRI) with 3D-transrectal ultrasound (TRUS) .
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with suspicion of prostate cancer
- •Patients who performed prostate mpMRI and F-Choline 18 PET scan
- •Patient capable of receiving clear informations
- •Patient giving a written consent for their participation via a consent signed by both parents of the patient (or legal tutor)
- •Patient covered by a healthcare insurance
Exclusion Criteria
- •Patients without suspect image of neoplasia after mpMRI and F-Choline 18 PET scan
Outcomes
Primary Outcomes
Number of image guided prostate biopsy in the zones detected by the TEP scan
Time Frame: at inclusion
Secondary Outcomes
- Number of image guided prostate biopsy in the zones detected by the mpMRI(at inclusion)